 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) compared with TACE in the treatment of patients with locally advanced hepatocellular carcinoma

Front Oncol: Stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) compared with TACE in the treatment of patients with locally advanced hepatocellular carcinoma

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

hazard analysis example

advanced structural technologies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Advanced hepatocellular carcinoma (HCC) has entered the age of immunotherapy

immunity

The study included patients with locally advanced HCC who were inoperable, refractory, or who refused surgical treatment

The study included 226 patients, 210 were initially treated with TACE, and 16 were treated with SBRT-IO

Infect

Among the 64 patients matched by PSM, the median tumor diameter was 10 cm (range: 3.

Multivariate analysis found that SBRT-IO was a good independent predictor of OS (HR = 0.

The ORR of the SBRT-IO group was significantly higher than that of the TACE group (87.

Among patients receiving TACE, the risk of TRAE ≥3 and treatment interruption due to toxicity was more common (60.

In summary, studies have shown that stereotactic radiotherapy (SBRT) combined with immunotherapy (SBRT-IO) in the treatment of patients with locally advanced hepatocellular carcinoma has a certain clinical effect, and its safety is controllable and tolerable, and it is worthy of further exploration

Original source:

Chiang CL, Chiu KW-H, Lee FA-S, Kong F-MS and Chan AC-Y (2021) Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.